Leumi ABL provides Sigma with £50m ABL facility

Asset-based lender Leumi ABL has agreed a new £50 million, four-year funding package with Sigma Pharmaceuticals, an independent pharmaceutical wholesaler in the UK. The facility is designed to support Sigma’s continued expansion and long-term growth strategy.

The Watford-based, family-owned business has been trading since 1982 and now supplies more than 3,000 pharmacies, 1,000 hospitals, and 600 dispensing doctors nationwide. Its portfolio spans generic and branded medicines, over-the-counter products, and its own line of generic medicines developed through the acquisition of product licences. Sigma has also diversified into new service areas to keep pace with the evolving community pharmacy sector.

The latest facility consolidates Sigma’s financing under Leumi ABL, following a previous three-year club arrangement with Leumi ABL and ABN Amro. The refinancing was executed swiftly to allow Sigma’s leadership team to remain focused on strategic priorities.

Bhavin Shah, Chief Financial Officer at Sigma Pharmaceuticals, said: “This refinancing marks a significant milestone for the Sigma Pharmaceuticals group, positioning us for a new phase of strategic growth and expansion. We are confident that this new facility will provide the flexibility and capital needed to achieve our long-term goals. We extend our sincere gratitude to the team at Leumi ABL for their continued support and partnership.”

Ryan Whitworth, Regional Sales Director at Leumi ABL, added: “Our long-standing relationship with Sigma allowed us to truly understand their business and goals, so we were able to structure a bespoke facility specifically tailored to support the business’ growth ambitions and deliver it at pace.

“With its strong track record, scale, and established network of customers, Sigma is well positioned, and we look forward to continue working with the business’ experienced team as they embark on the next phase of its growth journey.”